DDInter980 DDInter122
Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and parenteral formulations. Due to low solubility in water of isavuconazole on its own, the isovuconazonium formulation is favorable as it has high solubility in water and allows for intravenous administration. This formulation also avoids the use of a cyclodextrin vehicle for solubilization required for intravenous administration of other antifungals such as voriconazole and posaconazole, eliminating concerns of nephrotoxicity associated with cyclodextrin. Isovuconazonium has excellent
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
Isavuconazonium {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Isavuconazonium {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Isavuconazonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loratadine
Isavuconazonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Isavuconazonium {u} may lead to a major life threatening interaction when taken with {v} Apalutamide
Isavuconazonium {u} may lead to a major life threatening interaction when taken with {v} Cobimetinib
Isavuconazonium may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Isavuconazonium may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Loratadine
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Isavuconazonium may lead to a major life threatening interaction when taken with Apalutamide
Isavuconazonium may lead to a major life threatening interaction when taken with Cobimetinib